Drug Trial News

RSS

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Apr 2012

Enrollment complete for Ampio's multiple indication diagnostic clinical trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it has completed enrollment of patients for its multiple indication diagnostic clinical trials.

12 Apr 2012

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application for the Sufentanil NanoTab PCA System, ARX-01.

12 Apr 2012

First clinical trial to clearly demonstrate effective prevention of post-ERCP pancreatitis

A study in the current issue of the New England Journal of Medicine shows a serious complication of ERCP, a procedure commonly used to diagnose and treat problems of the bile and pancreatic ducts, may be eliminated with a single dose medication.

12 Apr 2012

FDA clears Cerecor’s FP01 IND for treatment of cough

Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration.

12 Apr 2012

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

12 Apr 2012

QRxPharma completes MoxDuo CR Phase 1 studies on chronic pain

QRxPharma announced today successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.

11 Apr 2012

Omeros initiates enrollment in second Phase 3 trial of OMS302

Omeros Corporation today announced that patient enrollment has begun in the Company's second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

10 Apr 2012

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

10 Apr 2012

Neutra to initiate new round of clinical trials on Pure Plus Weight Loss formula

Neutra Corp., an emerging provider of nutraceutical products, announced today that it's gearing up to start a new round of clinical trials on the company's Pure Plus Weight Loss formula, which now includes new ingredients raspberry ketone and African mango.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Preliminary findings from an FDA-approved clinical trial indicate that the experimental dietary supplement Prostate Health Cocktail (PHC) may arrest and in some cases lower rising PSA (Prostate Specific Antigen) in men with recurrent prostate cancer.

9 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012

USPTO issues Notice of Allowance for Sunshine Biopharma's anti-tumor compound patent application

Sunshine Biopharma Inc. is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a "Notice of Allowance" for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications.

9 Apr 2012

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Winston Pharmaceuticals, Inc.,, announced that the National Institutes of Health has awarded Winston a grant under the Small Business Innovation Research program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia of the trigeminal nerve.

9 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

Ampio submits pre-IND package on Zertane to FDA

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

9 Apr 2012

'Benefits and burdens' of participating in clinical research trials

In one of the first studies of its kind, University of Pennsylvania School of Nursing researchers have identified what cancer patients consider the "benefits and burdens" of participating in clinical research trials.

7 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

Drug Trial News

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Enrollment complete for Ampio's multiple indication diagnostic clinical trials

AcelRx commences dosing in second ARX-01 Phase 3 clinical trial for acute post-operative pain

First clinical trial to clearly demonstrate effective prevention of post-ERCP pancreatitis

FDA clears Cerecor’s FP01 IND for treatment of cough

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

QRxPharma completes MoxDuo CR Phase 1 studies on chronic pain

Omeros initiates enrollment in second Phase 3 trial of OMS302

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Neutra to initiate new round of clinical trials on Pure Plus Weight Loss formula

Proteonomix provides corporate and clinical trial updates

New dietary supplement may arrest, lower rising PSA in men with recurrent prostate cancer

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

USPTO issues Notice of Allowance for Sunshine Biopharma's anti-tumor compound patent application

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Ampio submits pre-IND package on Zertane to FDA

'Benefits and burdens' of participating in clinical research trials

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News